GASTROVIST Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Gastrovist, and when can generic versions of Gastrovist launch?
Gastrovist is a drug marketed by Bayer Hlthcare and is included in one NDA.
The generic ingredient in GASTROVIST is diatrizoate meglumine; diatrizoate sodium. There are eleven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the diatrizoate meglumine; diatrizoate sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Gastrovist
A generic version of GASTROVIST was approved as diatrizoate meglumine; diatrizoate sodium by ANDA REPOSITORY on June 27th, 2022.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for GASTROVIST?
- What are the global sales for GASTROVIST?
- What is Average Wholesale Price for GASTROVIST?
Summary for GASTROVIST
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | GASTROVIST at DailyMed |
US Patents and Regulatory Information for GASTROVIST
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Hlthcare | GASTROVIST | diatrizoate meglumine; diatrizoate sodium | SOLUTION;ORAL, RECTAL | 087728-001 | Sep 23, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
